GlassScriptPhysician profile
Poneh Rahimi
NPI 1255406401
$853.48
in general payments reported to CMS, 2019-2025
11 companies · $36.72 in 2025
The $36.72 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $62.41 · 2021: $260 · 2022: $203 · 2023: $176 · 2025: $36.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $283.98 | 2020-2023 | |
| Boston Scientific Corporation | $130.43 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $124.97 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.34 | 2019-2021 | |
| Alfasigma USA, INC. | $71.09 | 2020-2021 | |
| Janssen Biotech, INC. | $39.95 | 2022 | |
| Gilead Sciences, INC. | $36.72 | 2025 | Livdelzi |
| Apollo Endosurgery US INC | $32.60 | 2019 | |
| Daiichi Sankyo INC. | $26.84 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.11 | 2021 | |
| Allergan, INC. | $17.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poneh Rahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.